Clinical Trial Update: Study of Surufatinib Single Agent or Surufatinib Combined With Toripalimab in Patients With Advanced Solid Tumors [Phase 2]

View source ↗

Summary

Phase 2 trial update for surufatinib as a single agent or in combination with toripalimab in patients with advanced solid tumors has completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Solid Tumors

Drugs mentioned

• Surufatinib (Surufatinib)
• Toripalimab (Toripalimab)

Snippet

Sponsor: Hutchison Medipharma Limited | Conditions: Advanced Solid Tumors | Phase 2 | Status: COMPLETED